Local News
Live
Upvote
0
Downvote
Share
Save
Report
What’s more, even what seems like minor share price appreciation can result in massive percentage gains.
The data showed that pelareorep induced a robust anti-tumor immune response in some types of breast cancer.
Meanwhile, the BRACELET-1 Phase 2 study will evaluate efficacy of pelareorep in combination with Pfizer’s anti-PD-L1 mAb Bavencio in breast cancer.
A third Phase 2 breast cancer trial, IRENE, will evaluate pelareorep's ability to improve outcomes in triple-negative breast cancer.
ONCY strong pipeline and $3.01 share price have scored it substantial praise from the pros on Wall Street.
Published On: Tue, 23 Mar 2021 12:57:39 GMT
Not Available